Going from 0.25mg to 0.5mg Wegovy: what the first dose increase actually means

The myth: 0.25mg is just a smaller version of what's coming

The single biggest misconception about the early Wegovy schedule is that each dose is simply a fraction of the next, scaling up in a straight line to 2.4mg. That framing misses the point of the starter dose entirely. 0.25mg of semaglutide is a tolerability ramp, not a therapeutic one. Clinical trials and the licensed prescribing information are explicit: you should not expect measurable weight loss during your first four weeks. The dose is low enough to let your digestive system adapt to the way semaglutide slows gastric emptying and signals fullness, so that when the treatment doses begin, your body is less likely to respond with severe nausea or vomiting.

This is why the move to 0.5mg is genuinely significant. It is the point at which semaglutide starts doing what it is licensed to do. Patients who feel discouraged after a quiet first month are sometimes surprised by how differently 0.5mg feels, a quieter appetite, slower hunger returning after meals, or food feeling more filling than expected. That shift is not placebo; it reflects the change in pharmacological exposure. The NHS patient information for semaglutide describes this graduated schedule and explains why each stage exists.

Correcting this myth also protects against a separate problem: some people try to accelerate the schedule themselves, reasoning that faster is better. Dose changes for a prescription medicine are a clinical decision, not a personal preference.

What physically changes when you go to 0.5mg

Semaglutide works by activating GLP-1 receptors involved in appetite regulation and blood-sugar balance. At 0.25mg the effect on appetite is modest. At 0.5mg, and more so as the dose rises through 1mg, 1.7mg and eventually 2.4mg, the effect becomes more pronounced, slower gastric emptying, stronger and earlier satiety signals, and a reduction in the reward value many people associate with food. You can read about the full Wegovy dose schedule and what each level is designed to achieve.

In practical terms, the week following a dose increase is when most people notice side effects most acutely. Nausea is the most commonly reported, followed by loose stools, constipation, indigestion and (less often) fatigue or headache. These effects tend to peak in the first few days after the injection and ease by the end of the week, though that pattern varies. Eating smaller portions, avoiding very fatty meals around injection day, and staying well hydrated all help. If symptoms are severe or persistent, contact your prescriber before taking the next pen.

One thing the NHS semaglutide guidance is clear about: seek urgent medical help for severe, persistent stomach pain that radiates to the back, this could indicate pancreatitis, a rare but serious reaction that the MHRA has specifically highlighted for GLP-1 medicines. Report any suspected side effect via the Yellow Card scheme.

What your prescriber is checking before approving the step up

The move from 0.25mg to 0.5mg is not automatic. A prescriber needs to be satisfied that you have tolerated the starter dose without serious adverse effects and that there are no new contraindications before approving the next pen. At a regulated online pharmacy this means a clinical review, not a checkbox, a prescriber reads your update and makes a considered decision. That review also checks that the pen you receive next is the right one. Wegovy currently comes as a pre-filled subcutaneous injection; the pen for each dose strength is distinct, and your supply is confirmed during the clinical assessment.

If side effects at 0.25mg were significant, a prescriber may suggest staying at the starter dose for a further four weeks before stepping up. That is not a setback; it is the titration schedule working as intended. The general guidance on moving up a Wegovy dose covers this principle across every step in the ladder, not just the first.

For people wondering whether it is ever appropriate to jump over 0.5mg entirely, the short answer is no, and our page on skipping from 0.25mg to 1mg explains why that is not part of the licensed schedule and what the risks would be. The licensed dose ladder exists because the evidence supporting Wegovy was built on a specific titration sequence; deviating from it is a prescribing decision with real clinical implications.

The practicalities: your new pen and what to expect on injection day

When your 0.5mg pen is approved and dispatched, it arrives via DPD in plain, unbranded packaging, tracked to your door. The pen looks similar to the 0.25mg one but is clearly labelled with the strength; always double-check before injecting. Subcutaneous injection sites are the abdomen, thigh or upper arm; rotating between them reduces the chance of skin irritation at any single spot. For the exact storage and handling instructions (including the refrigeration requirement and what to do if the pen has been out of the fridge) the definitive source is the Patient Information Leaflet that comes with your pen, not a website.

Wegovy is a prescription-only medicine. The private cost of treatment is one consideration for many people, and our Wegovy price comparison page sets out what a legitimate UK price typically includes and why clinical oversight is a meaningful part of that. If you are weighing up whether to continue after 0.5mg or are unsure about the next step, the right conversation is with your prescriber, not a forum, and anyone approaching the upper end of the schedule may also find it helpful to read our guidance on going from 1.7mg to 2.4mg to understand what that final increase involves. For broader context on what the full treatment journey looks like, our weight-loss treatment overview covers how GLP-1 medicines fit into a longer-term plan.